论文部分内容阅读
目的观察奈达铂对食管癌患者的临床治疗效果。方法将64例食管癌患者随机分为治疗组和对照组各32例。治疗组采取奈达铂联合5-氟尿嘧啶(5-FU)进行治疗,对照组采取顺铂(DDP)联合5-FU进行治疗,21d为1个疗程,连用2个疗程。对比2组患者治疗的总有效率、不良反应的发生率以。结果治疗组的总有效率为53.1%,恶心呕吐的发生率为21.9%,肾功能异常的发生率为12.5%;对照组则分别为28.1%、46.9%及34.4%。2组比较,治疗的总有效率、恶心呕吐的发生率以及肾功能异常的发生率差异均有统计学意义(P<0.05),其他不良反应无明显差异。结论奈达铂联合5-FU治疗食管癌可显著提高治疗的总有效率,不良反应小,值得临床上推广使用。
Objective To observe the clinical efficacy of nedaplatin in patients with esophageal cancer. Methods 64 cases of esophageal cancer were randomly divided into treatment group and control group of 32 cases. The treatment group was treated with nedaplatin combined with 5-fluorouracil (5-FU), the control group with cisplatin (DDP) combined with 5-FU for treatment, 21d for a course of treatment, once every 2 courses. The total effective rate of two groups of patients compared with the incidence of adverse reactions to. Results The total effective rate was 53.1% in the treatment group, nausea and vomiting was 21.9%, and the incidence of renal dysfunction was 12.5%. The control group was 28.1%, 46.9% and 34.4% respectively. The total effective rate of treatment, the incidence of nausea and vomiting and the incidence of renal dysfunction were statistically different between the two groups (P <0.05). There was no significant difference in other adverse reactions. Conclusion Nedaplatin and 5-FU treatment of esophageal cancer can significantly improve the total effective rate of treatment, adverse reactions, it is worth promoting the use of the clinic.